Pyrazinamide

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 141-144

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETEST; ALLOPURINOL; ETHAMBUTOL; ISONIAZID; PIRALDINA; PYRAZINAMIDE; RIFAMPICIN; RIFATER; STREPTOMYCIN; UNIPYRANAMIDE;

ADD ON THERAPY; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL MUTATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BLOOD CLOTTING DISORDER; CARCINOGENICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSURIA; ENZYME ACTIVITY; ESCHERICHIA COLI; FEVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; LIVER TOXICITY; MACROPHAGE; MALAISE; MEMBRANE POTENTIAL; MEMBRANE TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA AND VOMITING; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PYROCOCCUS HORIKOSHII; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SINGLE DRUG DOSE; TUBERCULOSIS; URIC ACID BLOOD LEVEL; URINALYSIS;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; PYRAZINAMIDE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249092119     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70021-0     Document Type: Review

References (24)

1. Sriram D., et al. Synthesis of pyrazinamide Mannich bases and its antitubercular properties. Bioorg Med Chem Lett 16 (2006) 2113-2116
2. Boshoff H., et al. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 184 (2002) 2167-2172
3. Zhang Y., et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52 (2003) 790-795
4. Zhang Y., and Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7 (2003) 6-21
5. Wade M., and Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 53 (2004) 769-773
6. Wade M., and Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 58 (2006) 936-941
7. Davies A., et al. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility. J Clin Microbiol 38 (2000) 3686-3688
8. Scorpio A., et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41 (1997) 540-543
9. Du X., et al. Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 40 (2001) 14166-14172
10. Salfinger M., and Heifets L. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32 (1988) 1002-1004
11. Hu Y., et al. Sterilising action of pyrazinamide in models of dormant MTB. Int J Tuberc Lung Dis 10 (2006) 317-322
12. Teyssier L. Higher activity of morphazinamide over pyrazinamide against intracellular Mycobacterium tuberculosis. Int J Tuberc Lung Dis 5 (2001) 386-398
13. Wallis R., et al. A whole blood bactericidal assay for tuberculosis. J Infect. Dis 83 (2001) 1300-1303
14. Grosset J., et al. Antagonism between isoniazid and the combination pyrazinamide rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36 (1992) 548-551
15. McCune R., and Thompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 104 (1956) 737-762
16. McCune R., et al. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104 (1956) 763-802
17. Grosset J., and Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharan P., and Jenkins P. (Eds). Mycobacteria: II. Chemotherapy (1998), Chapman and Hall 51-97
18. Mitchison D. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4 (2000) 796-806
19. Pandey R., et al. Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52 (2003) 981-986
20. Pandey R., et al. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 23 (2004) 414-415
21. Qurrat-ul-Ain, et al. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother 51 (2003) 931-938
22. Pari L., and Kumar N. Hepatoprotective activity of Moringa oleifera on antitubercular drug-induced liver damage in rats. J Med Food 5 (2002) 171-177
23. ®) Mice. NIH Publication 97 3938, 1997 (1997), United States Department of Health and Human Services, Public Health Service, National Institutes of Health
24. Chan E., et al. Pyrazinamide, ethambutol, ethionamide, and aminoglycosides. In: Rom W., and Garay S. (Eds). Tuberculosis. 2nd edition (2003), Lippincott Williams & Wilkins, Philadelphia, PA 773-789